Who to call at Korsana Biosciences, and when

Fundz watches for the moments Korsana Biosciences starts buying, and tells you who to reach.

An alert the day Korsana Biosciences raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Korsana Biosciences, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Korsana Biosciences. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Cyclerion Therapeutics Enters Licensing Agreement with MIT to Advance Treatment-Resistant Depression Therapies

Sep 23, 2025

Contract Type

agreement

WalthamBiotechnologyHealthcareHealth CareTherapeutics

Description

Cyclerion Therapeutics has secured a licensing agreement with the Massachusetts Institute of Technology, marking a significant step in its strategic relaunch. This agreement will provide the intellectual property necessary for Cyclerion to advance its Phase 2 programs focused on innovative treatments for neuropsychiatric conditions, particularly treatment-resistant depression.

Company Information

Company

Korsana Biosciences

Location

Waltham, Massachusetts, United States

About

Korsana Biosciences, Inc. is a biotechnology company focused on discovering and developing novel therapies for neurodegenerative diseases, particularly Alzheimer's disease. The company leverages its proprietary THETA™ therapeutic targeting platform to improve drug delivery and efficacy. Founded in 2024, Korsana aims to elevate patient care by creating potentially best-in-class therapeutics. The company's lead program, KRSA-028, targets amyloid beta and demonstrates strong preclinical data.